These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1792441)

  • 21. Effects of various fibrates on serum alkaline phosphatase activity.
    Ganotakis E; Tsimihodimos V; Bairaktari E; Rizos E; Athyros V; Seferiades C; Elisaf M
    Atherosclerosis; 2002 Nov; 165(1):187-8. PubMed ID: 12208487
    [No Abstract]   [Full Text] [Related]  

  • 22. [Autoimmune hepatitis induced by fibrates].
    Ganne-Carrié N; de Leusse A; Guettier C; Castera L; Levecq H; Bertrand HJ; Plumet Y; Trinchet JC; Beaugrand M
    Gastroenterol Clin Biol; 1998 May; 22(5):525-9. PubMed ID: 9762291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.
    Maiguma T; Fujisaki K; Itoh Y; Makino K; Teshima D; Takahashi-Yanaga F; Sasaguri T; Oishi R
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):289-96. PubMed ID: 12644902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrates and HDL cholesterol.
    Murphy MJ; Packard CJ; O'Reilly DS
    Ann Clin Biochem; 1997 Jan; 34 ( Pt 1)():114. PubMed ID: 9022900
    [No Abstract]   [Full Text] [Related]  

  • 25. Acute muscular syndrome after bezafibrate.
    Bock KD
    Klin Wochenschr; 1981 Dec; 59(23):1321. PubMed ID: 7311399
    [No Abstract]   [Full Text] [Related]  

  • 26. Tolerability of fibric acids. Comparative data and biochemical bases.
    Sirtori CR; Calabresi L; Werba JP; Franceschini G
    Pharmacol Res; 1992; 26(3):243-60. PubMed ID: 1437989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats.
    Lupp A; Karge E; Deufel T; Oelschlägers H; Fleck C
    Arzneimittelforschung; 2008; 58(5):225-41. PubMed ID: 18589557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lipid profiles on fibric-acid derivatives.
    Capps NE
    Lancet; 1994 Sep; 344(8923):684-5. PubMed ID: 7915370
    [No Abstract]   [Full Text] [Related]  

  • 29. Abnormal lipid profiles on fibrate derivatives.
    McLeod AJ; Warren RJ; Armitage M
    Lancet; 1996 Jan; 347(8996):261. PubMed ID: 8551900
    [No Abstract]   [Full Text] [Related]  

  • 30. The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
    Schonfeld G
    Atherosclerosis; 1994 Dec; 111(2):161-74. PubMed ID: 7718018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
    Davidson MH
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):341-2. PubMed ID: 19844785
    [No Abstract]   [Full Text] [Related]  

  • 32. Paradoxical high-density lipoprotein reduction induced by fenofibrate and ciprofibrate.
    Collinson PO; Hjelm CJ; Canepo-Anson R
    Ann Clin Biochem; 1996 Mar; 33 ( Pt 2)():159-61. PubMed ID: 8729728
    [No Abstract]   [Full Text] [Related]  

  • 33. Efficacy and safety of ciprofibrate in hyperlipoproteinaemias.
    Turpin G; Bruckert E
    Atherosclerosis; 1996 Jul; 124 Suppl():S83-7. PubMed ID: 8831920
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?
    Broeders N; Knoop C; Antoine M; Tielemans C; Abramowicz D
    Nephrol Dial Transplant; 2000 Dec; 15(12):1993-9. PubMed ID: 11096145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ciprofibrate and lipid profile.
    Chandler HA; Batchelor AJ
    Lancet; 1994 Jul; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract]   [Full Text] [Related]  

  • 36. Implication of fibrate therapy for homocysteine.
    Goffin E; Jamar F; Desager JP; Devuyst O
    Lancet; 1999 Oct; 354(9185):1209. PubMed ID: 10513738
    [No Abstract]   [Full Text] [Related]  

  • 37. [The pharmacokinetics of hypolipemic agents. 10. The dehalogenation of the hypolipemic agent ciprofibrate].
    Oelschläger H; Hellwich KH; Rothley D
    Arch Pharm (Weinheim); 1994 Apr; 327(4):261-5. PubMed ID: 8204026
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibrates and C-reactive protein.
    Kostoula A; Elisaf M
    Clin Chim Acta; 2003 Feb; 328(1-2):197. PubMed ID: 12559619
    [No Abstract]   [Full Text] [Related]  

  • 39. [Treatment of familial combined hyperlipidemia].
    Bruckert E
    Ann Endocrinol (Paris); 1997; 58(4):297-301. PubMed ID: 9436478
    [No Abstract]   [Full Text] [Related]  

  • 40. A case of rhabdomyolysis and thromboembolic event secondary to fibrate monotherapy.
    Yildiz A; Gucuk E; Cay S
    Acta Cardiol; 2008 Aug; 63(4):515-7. PubMed ID: 18795591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.